Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Hepatic thrombopoietin gene silencing reduces platelet count and breast cancer progression in transgenic MMTV-PyMT mice.

Shirai T, Revenko AS, Tibbitts J, Ngo ATP, Mitrugno A, Healy LD, Johnson J, Tucker EI, Hinds MT, Coussens LM, McCarty OJT, Monia BP, Gruber A.

Blood Adv. 2019 Oct 22;3(20):3080-3091. doi: 10.1182/bloodadvances.2019000250.

PMID:
31648335
2.

The TLR7/8 agonist R848 remodels tumor and host responses to promote survival in pancreatic cancer.

Michaelis KA, Norgard MA, Zhu X, Levasseur PR, Sivagnanam S, Liudahl SM, Burfeind KG, Olson B, Pelz KR, Angeles Ramos DM, Maurer HC, Olive KP, Coussens LM, Morgan TK, Marks DL.

Nat Commun. 2019 Oct 15;10(1):4682. doi: 10.1038/s41467-019-12657-w.

3.

Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 Jul 4;7(1):167. doi: 10.1186/s40425-019-0640-y.

4.

Macrophages and Metabolism in the Tumor Microenvironment.

Vitale I, Manic G, Coussens LM, Kroemer G, Galluzzi L.

Cell Metab. 2019 Jul 2;30(1):36-50. doi: 10.1016/j.cmet.2019.06.001. Review.

PMID:
31269428
5.

Innate αβ T Cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.

Hundeyin M, Kurz E, Mishra A, Rossi JAK, Liudahl SM, Leis KR, Mehrotra H, Kim M, Torres LE, Ogunsakin A, Link J, Sears RC, Sivagnanam S, Goecks J, Islam KMS, Dolgalev I, Savadkar S, Wang W, Aykut B, Leinwand J, Diskin B, Adam S, Israr M, Gelas M, Lish J, Chin K, Farooq MS, Wadowski B, Wu J, Shah S, Adeegbe DO, Pushalkar S, Vasudevaraja V, Saxena D, Wong KK, Coussens LM, Miller G.

Cancer Discov. 2019 Sep;9(9):1288-1305. doi: 10.1158/2159-8290.CD-19-0161. Epub 2019 Jul 2.

PMID:
31266770
6.

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Hassan R, Alley E, Kindler H, Antonia S, Jahan T, Honarmand S, Nair N, Whiting CC, Enstrom A, Lemmens E, Tsujikawa T, Kumar S, Choe G, Thomas A, McDougall K, Murphy AL, Jaffee E, Coussens LM, Brockstedt DG.

Clin Cancer Res. 2019 Oct 1;25(19):5787-5798. doi: 10.1158/1078-0432.CCR-19-0070. Epub 2019 Jul 1.

PMID:
31263030
7.

Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors.

Wesolowski R, Sharma N, Reebel L, Rodal MB, Peck A, West BL, Marimuthu A, Severson P, Karlin DA, Dowlati A, Le MH, Coussens LM, Rugo HS.

Ther Adv Med Oncol. 2019 Jun 21;11:1758835919854238. doi: 10.1177/1758835919854238. eCollection 2019.

8.

Dissecting the Stromal Signaling and Regulation of Myeloid Cells and Memory Effector T Cells in Pancreatic Cancer.

Blair AB, Kim VM, Muth ST, Saung MT, Lokker N, Blouw B, Armstrong TD, Jaffee EM, Tsujikawa T, Coussens LM, He J, Burkhart RA, Wolfgang CL, Zheng L.

Clin Cancer Res. 2019 Sep 1;25(17):5351-5363. doi: 10.1158/1078-0432.CCR-18-4192. Epub 2019 Jun 11.

PMID:
31186314
9.

Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop.

Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM; Society for Immunotherapy of Cancer (SITC) Cancer Immune Responsiveness Task Force and Working Groups.

J Immunother Cancer. 2019 May 22;7(1):131. doi: 10.1186/s40425-019-0602-4. Review. Erratum in: J Immunother Cancer. 2019 Jul 4;7(1):167.

10.

Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.

Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:165-174. doi: 10.1200/EDBK_237987. Epub 2019 May 17.

PMID:
31099649
11.

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA.

Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1.

PMID:
31043414
12.

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.

Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW.

Cancer Cell. 2019 Apr 15;35(4):588-602.e10. doi: 10.1016/j.ccell.2019.02.009. Epub 2019 Mar 28.

13.

Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status.

Means C, Clayburgh DR, Maloney L, Sauer D, Taylor MH, Shindo ML, Coussens LM, Tsujikawa T.

Head Neck. 2019 Aug;41(8):2636-2646. doi: 10.1002/hed.25740. Epub 2019 Mar 21.

PMID:
30896061
14.

Robust Cell Detection and Segmentation for Image Cytometry Reveal Th17 Cell Heterogeneity.

Tsujikawa T, Thibault G, Azimi V, Sivagnanam S, Banik G, Means C, Kawashima R, Clayburgh DR, Gray JW, Coussens LM, Chang YH.

Cytometry A. 2019 Apr;95(4):389-398. doi: 10.1002/cyto.a.23726. Epub 2019 Feb 4.

PMID:
30714674
15.

Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models.

Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M.

Nat Cell Biol. 2019 Feb;21(2):190-202. doi: 10.1038/s41556-018-0256-3. Epub 2018 Dec 31.

16.

Complement C5a Fosters Squamous Carcinogenesis and Limits T Cell Response to Chemotherapy.

Medler TR, Murugan D, Horton W, Kumar S, Cotechini T, Forsyth AM, Leyshock P, Leitenberger JJ, Kulesz-Martin M, Margolin AA, Werb Z, Coussens LM.

Cancer Cell. 2018 Oct 8;34(4):561-578.e6. doi: 10.1016/j.ccell.2018.09.003.

17.

Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer.

Pennock ND, Martinson HA, Guo Q, Betts CB, Jindal S, Tsujikawa T, Coussens LM, Borges VF, Schedin P.

J Immunother Cancer. 2018 Oct 1;6(1):98. doi: 10.1186/s40425-018-0406-y.

18.

Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival.

Gast CE, Silk AD, Zarour L, Riegler L, Burkhart JG, Gustafson KT, Parappilly MS, Roh-Johnson M, Goodman JR, Olson B, Schmidt M, Swain JR, Davies PS, Shasthri V, Iizuka S, Flynn P, Watson S, Korkola J, Courtneidge SA, Fischer JM, Jaboin J, Billingsley KG, Lopez CD, Burchard J, Gray J, Coussens LM, Sheppard BC, Wong MH.

Sci Adv. 2018 Sep 12;4(9):eaat7828. doi: 10.1126/sciadv.aat7828. eCollection 2018 Sep.

19.

Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy.

Li J, Byrne KT, Yan F, Yamazoe T, Chen Z, Baslan T, Richman LP, Lin JH, Sun YH, Rech AJ, Balli D, Hay CA, Sela Y, Merrell AJ, Liudahl SM, Gordon N, Norgard RJ, Yuan S, Yu S, Chao T, Ye S, Eisinger-Mathason TSK, Faryabi RB, Tobias JW, Lowe SW, Coussens LM, Wherry EJ, Vonderheide RH, Stanger BZ.

Immunity. 2018 Jul 17;49(1):178-193.e7. doi: 10.1016/j.immuni.2018.06.006. Epub 2018 Jun 26.

20.

Understanding the tumor immune microenvironment (TIME) for effective therapy.

Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI, Ostrand-Rosenberg S, Hedrick CC, Vonderheide RH, Pittet MJ, Jain RK, Zou W, Howcroft TK, Woodhouse EC, Weinberg RA, Krummel MF.

Nat Med. 2018 May;24(5):541-550. doi: 10.1038/s41591-018-0014-x. Epub 2018 Apr 23. Review.

21.

TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast Cancer.

de Mingo Pulido Á, Gardner A, Hiebler S, Soliman H, Rugo HS, Krummel MF, Coussens LM, Ruffell B.

Cancer Cell. 2018 Jan 8;33(1):60-74.e6. doi: 10.1016/j.ccell.2017.11.019.

22.

B cells as biomarkers: predicting immune checkpoint therapy adverse events.

Liudahl SM, Coussens LM.

J Clin Invest. 2018 Feb 1;128(2):577-579. doi: 10.1172/JCI99036. Epub 2018 Jan 8.

23.

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman K, Wei SC, Cogdill AP, Zhao L, Hudgens CW, Hutchinson DS, Manzo T, Petaccia de Macedo M, Cotechini T, Kumar T, Chen WS, Reddy SM, Szczepaniak Sloane R, Galloway-Pena J, Jiang H, Chen PL, Shpall EJ, Rezvani K, Alousi AM, Chemaly RF, Shelburne S, Vence LM, Okhuysen PC, Jensen VB, Swennes AG, McAllister F, Marcelo Riquelme Sanchez E, Zhang Y, Le Chatelier E, Zitvogel L, Pons N, Austin-Breneman JL, Haydu LE, Burton EM, Gardner JM, Sirmans E, Hu J, Lazar AJ, Tsujikawa T, Diab A, Tawbi H, Glitza IC, Hwu WJ, Patel SP, Woodman SE, Amaria RN, Davies MA, Gershenwald JE, Hwu P, Lee JE, Zhang J, Coussens LM, Cooper ZA, Futreal PA, Daniel CR, Ajami NJ, Petrosino JF, Tetzlaff MT, Sharma P, Allison JP, Jenq RR, Wargo JA.

Science. 2018 Jan 5;359(6371):97-103. doi: 10.1126/science.aan4236. Epub 2017 Nov 2.

24.

Multiplexed immunohistochemistry image analysis using sparse coding.

Young Hwan Chang, Tsujikawa T, Margolin A, Coussens LM, Gray JW.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:4046-4049. doi: 10.1109/EMBC.2017.8037744.

PMID:
29060785
25.

Workshop on challenges, insights, and future directions for mouse and humanized models in cancer immunology and immunotherapy: a report from the associated programs of the 2016 annual meeting for the Society for Immunotherapy of cancer.

Zloza A, Karolina Palucka A, Coussens LM, Gotwals PJ, Headley MB, Jaffee EM, Lund AW, Sharpe AH, Sznol M, Wainwright DA, Wong KK, Bosenberg MW.

J Immunother Cancer. 2017 Sep 19;5(1):77. doi: 10.1186/s40425-017-0278-6.

26.

Surgical Procedures and Methodology for a Preclinical Murine Model of De Novo Mammary Cancer Metastasis.

Gast CE, Shaw AK, Wong MH, Coussens LM.

J Vis Exp. 2017 Jul 29;(125). doi: 10.3791/54852.

27.

Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition.

Gil Del Alcazar CR, Huh SJ, Ekram MB, Trinh A, Liu LL, Beca F, Zi X, Kwak M, Bergholtz H, Su Y, Ding L, Russnes HG, Richardson AL, Babski K, Min Hui Kim E, McDonnell CH 3rd, Wagner J, Rowberry R, Freeman GJ, Dillon D, Sorlie T, Coussens LM, Garber JE, Fan R, Bobolis K, Allred DC, Jeong J, Park SY, Michor F, Polyak K.

Cancer Discov. 2017 Oct;7(10):1098-1115. doi: 10.1158/2159-8290.CD-17-0222. Epub 2017 Jun 26.

28.

Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis.

Tsujikawa T, Kumar S, Borkar RN, Azimi V, Thibault G, Chang YH, Balter A, Kawashima R, Choe G, Sauer D, El Rassi E, Clayburgh DR, Kulesz-Martin MF, Lutz ER, Zheng L, Jaffee EM, Leyshock P, Margolin AA, Mori M, Gray JW, Flint PW, Coussens LM.

Cell Rep. 2017 Apr 4;19(1):203-217. doi: 10.1016/j.celrep.2017.03.037.

29.

Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.

Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, Kelley KA, Lopez CD, Rana SR, Ruhl R, Tsikitis VL, Vaccaro GM, Wong MH, Mayo SC.

Cell Mol Gastroenterol Hepatol. 2017 Jan 20;3(2):163-173. doi: 10.1016/j.jcmgh.2017.01.006. eCollection 2017 Mar. Review.

30.

MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment.

Wilson R, Espinosa-Diez C, Kanner N, Chatterjee N, Ruhl R, Hipfinger C, Advani SJ, Li J, Khan OF, Franovic A, Weis SM, Kumar S, Coussens LM, Anderson DG, Chen CC, Cheresh DA, Anand S.

Nat Commun. 2016 Nov 25;7:13597. doi: 10.1038/ncomms13597.

31.

Iron oxide nanoparticles inhibit tumour growth by inducing pro-inflammatory macrophage polarization in tumour tissues.

Zanganeh S, Hutter G, Spitler R, Lenkov O, Mahmoudi M, Shaw A, Pajarinen JS, Nejadnik H, Goodman S, Moseley M, Coussens LM, Daldrup-Link HE.

Nat Nanotechnol. 2016 Nov;11(11):986-994. doi: 10.1038/nnano.2016.168. Epub 2016 Sep 26.

32.

Trim32 Deficiency Enhances Th2 Immunity and Predisposes to Features of Atopic Dermatitis.

Liu Y, Wang Z, De La Torre R, Barling A, Tsujikawa T, Hornick N, Hanifin J, Simpson E, Wang Y, Swanzey E, Wortham A, Ding H, Coussens LM, Kulesz-Martin M.

J Invest Dermatol. 2017 Feb;137(2):359-366. doi: 10.1016/j.jid.2016.09.020. Epub 2016 Oct 5.

33.

AACR Cancer Progress Report 2016.

Davidson NE, Armstrong SA, Coussens LM, Cruz-Correa MR, DeBerardinis RJ, Doroshow JH, Foti M, Hwu P, Kensler TW, Morrow M, Mulligan CG, Pao W, Platz EA, Smith TJ, Willman CL.

Clin Cancer Res. 2016 Oct 1;22 Suppl 19:S1-S137. No abstract available.

34.

Alk5 inhibition increases delivery of macromolecular and protein-bound contrast agents to tumors.

Daldrup-Link HE, Mohanty S, Ansari C, Lenkov O, Shaw A, Ito K, Hong SH, Hoffmann M, Pisani L, Boudreau N, Gambhir SS, Coussens LM.

JCI Insight. 2016 May 6;1(6). pii: e85608.

35.

Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, Glitza IC, Diab A, Vence LM, Rodriguez-Canales J, Parra ER, Wistuba II, Coussens LM, Sharpe AH, Flaherty KT, Gershenwald JE, Chin L, Davies MA, Clise-Dwyer K, Allison JP, Sharma P, Wargo JA.

Oncoimmunology. 2016 Feb 2;5(3):e1136044. eCollection 2016 Mar.

36.

The Basis of Oncoimmunology.

Palucka AK, Coussens LM.

Cell. 2016 Mar 10;164(6):1233-1247. doi: 10.1016/j.cell.2016.01.049. Review.

37.

Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer.

Gunderson AJ, Kaneda MM, Tsujikawa T, Nguyen AV, Affara NI, Ruffell B, Gorjestani S, Liudahl SM, Truitt M, Olson P, Kim G, Hanahan D, Tempero MA, Sheppard B, Irving B, Chang BY, Varner JA, Coussens LM.

Cancer Discov. 2016 Mar;6(3):270-85. doi: 10.1158/2159-8290.CD-15-0827. Epub 2015 Dec 29. Erratum in: Cancer Discov. 2016 Jul;6(7):802.

38.

Lymphatic Vessels, Inflammation, and Immunity in Skin Cancer.

Lund AW, Medler TR, Leachman SA, Coussens LM.

Cancer Discov. 2016 Jan;6(1):22-35. doi: 10.1158/2159-8290.CD-15-0023. Epub 2015 Nov 9. Review.

39.
40.

Senescence and cancer: An evolving inflammatory paradox.

Ruhland MK, Coussens LM, Stewart SA.

Biochim Biophys Acta. 2016 Jan;1865(1):14-22. doi: 10.1016/j.bbcan.2015.10.001. Epub 2015 Oct 8. Review.

41.

Myeloid Cells as Targets for Therapy in Solid Tumors.

Cotechini T, Medler TR, Coussens LM.

Cancer J. 2015 Jul-Aug;21(4):343-50. doi: 10.1097/PPO.0000000000000132. Review.

42.

Macrophages and therapeutic resistance in cancer.

Ruffell B, Coussens LM.

Cancer Cell. 2015 Apr 13;27(4):462-72. doi: 10.1016/j.ccell.2015.02.015. Epub 2015 Apr 6. Review.

43.

TH2-Polarized CD4(+) T Cells and Macrophages Limit Efficacy of Radiotherapy.

Shiao SL, Ruffell B, DeNardo DG, Faddegon BA, Park CC, Coussens LM.

Cancer Immunol Res. 2015 May;3(5):518-25. doi: 10.1158/2326-6066.CIR-14-0232. Epub 2015 Feb 25.

44.

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CM, Pryer N, Daniel D, Hwang ES, Rugo HS, Coussens LM.

Cancer Cell. 2014 Nov 10;26(5):623-37. doi: 10.1016/j.ccell.2014.09.006. Epub 2014 Oct 16.

45.

Duality of the immune response in cancer: lessons learned from skin.

Medler TR, Coussens LM.

J Invest Dermatol. 2014 Oct 10;134(e1):E23-8. doi: 10.1038/skinbio.2014.5. Review. No abstract available.

46.

Manipulating microRNAs to regulate macrophage polarization in gliomas.

Anand S, Coussens LM.

J Natl Cancer Inst. 2014 Aug 18;106(8). pii: dju230. doi: 10.1093/jnci/dju230. Print 2014 Aug. No abstract available.

PMID:
25136034
47.

Mammary gland involution as an immunotherapeutic target for postpartum breast cancer.

Fornetti J, Martinson HA, Betts CB, Lyons TR, Jindal S, Guo Q, Coussens LM, Borges VF, Schedin P.

J Mammary Gland Biol Neoplasia. 2014 Jul;19(2):213-28. doi: 10.1007/s10911-014-9322-z. Epub 2014 Jun 22. Review.

48.

B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.

Affara NI, Ruffell B, Medler TR, Gunderson AJ, Johansson M, Bornstein S, Bergsland E, Steinhoff M, Li Y, Gong Q, Ma Y, Wiesen JF, Wong MH, Kulesz-Martin M, Irving B, Coussens LM.

Cancer Cell. 2014 Jun 16;25(6):809-821. doi: 10.1016/j.ccr.2014.04.026. Epub 2014 Jun 5.

49.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

50.

CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8+ T cells.

Strachan DC, Ruffell B, Oei Y, Bissell MJ, Coussens LM, Pryer N, Daniel D.

Oncoimmunology. 2013 Dec 1;2(12):e26968. Epub 2013 Dec 4.

Supplemental Content

Loading ...
Support Center